1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015

Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015" provides an overview of Heterozygous familial hypercholesterolemia (heFH) clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Heterozygous familial hypercholesterolemia (heFH) 33
Nov 10, 2015: Regeneron and Sanofi Announce New Praluent Injection Analyses Presented at AHA Scientific Sessions 2015 33
Clinical Trial Profile Snapshots 35
Appendix 88
Abbreviations 88
Definitions 88
Research Methodology 89
Secondary Research 89
About GlobalData 90
Contact Us 90
Disclaimer 90
Source 91

List of Tables
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 16
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 20
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Phase, 2015* 23
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

List of Figures
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Heterozygous familial hypercholesterolemia (heFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 19
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24
Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Heterozygous familial hypercholesterolemia (heFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)

Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Global Market for Lipid Regulators accounted for $XX billion in 2014 and the market size is estimated to grow up to $XX billion by 2020 with CAGR at XX%. Lipid regulators or lipid-regulating drugs ...

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.